Ethex extends recall of oversized tablets
This article was originally published in Scrip
KV Pharmaceutical's Ethex generics division has expanded its recall of medicines that may contain oversized tablets with twice the intended level of active ingredient. Last month the company recalled three lots of dextroamphetamine 5mg tablets. The recall has now been extended to multiple lots of propafenone HCl 150mg, 225mg, and 300mg tablets; isosorbide mononitrate extended-release 30mg and 60mg tablets; morphine sulphate extended-release 15mg tablets; morphine sulphate immediate-release 15mg and 30mg tablets; and dextroamphetamine sulfate 10mg tablets. The products are being recalled to the consumer level, and Ethex is instructing pharmacies to contact consumers who were dispensed the drugs for replacement and/or refund.
You may also be interested in...
US FDA drugs center’s ambitious guidance agenda lists 105 new or revised guidances, most of which carried over from the prior year; new to the list are three guidances each on real-world data and individualized antisense oligonucleotide drug products, and a document focused on demonstrating efficacy with a single adequate and well-controlled trial.
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
Office of New Drugs Director Peter Stein tells the Pink Sheet that last phase of massive reorg was complicated by pandemic restrictions that forced review staff to work remotely, but the structural overhaul resulted in smaller, more nimble review groups and the breaking down of silos that ultimately helped the agency’s response to the public health crisis.